Clinical trials: Human Experimentation
Gastric Acid, Human Experimentation
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7.
- Trial name
- NCT00674115
- Testing
- Omeprazole/sodium bicarbonate, omeprazole magnesium, sodium bicarbonate
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Gastric Acid, Human Experimentation
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
Open-label randomized crossover design study. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7.
- Trial name
- NCT00765206
- Testing
- Omeprazole/sodium bicarbonate, omeprazole magnesium (20 mg equivalent)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Blood Pressure, Human Experimentation
Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)
Randomized, placebo-controlled double-blind, crossover design study; 116 subjects randomized on Day 1 to obtain 98 completed subjects.
- Trial name
- NCT00874120
- Testing
- Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Bayer
Human Experimentation
Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)
This study will determine differences between Proton Pump Inhibitors (PPI) formulations relative to their effects on gastric acidity.
- Trial name
- NCT01005719
- Testing
- Zegerid, Prevacid®
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Bayer
Human Experimentation (Human Volunteers)
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
This phase I trial will evaluate the effects of rupatadine, at a dose of 10 mg OD (authorised and marketed dose) and the 100mg/day (supratherapeutic dose) on the ECG parameters with a special focus on its effect on cardiac…
- Trial name
- NCT00199225
- Testing
- Rupatadine, moxifloxacin, Continous electrocardiographic register
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company